
Considering the Patient in Pediatric Drug Development
How Good Intentions Turned Into Harm
- 414 pages
- English
- ePUB (mobile friendly)
- Available on iOS & Android
Considering the Patient in Pediatric Drug Development
How Good Intentions Turned Into Harm
About this book
Considering the Patient in Pediatric Drug Development: How Good Intentions Turned into Harm addresses a fundamental challenge in drug development and healthcare for young patients. In clinical trials and clinical practice, the term "children" is used ambiguously to confer physiological characteristics to a chronological age limit, which in reality does not exist. This book outlines why the United States (US) and European Union's (EU) regulatory authorities, pediatric academia, and the pharmaceutical industry demand, support and perform pediatric drug studies, along with the key flaws of this demand that blurs the different administrative and physiological meanings of the term "child."In addition, the book covers why most pediatric regulatory studies lack medical sense and many even harm young patients and the conflicts of interest behind pediatric drug studies. It includes relevant information about the maturation of the human body regarding absorption, distribution, metabolism and excretion of food and drugs as well as key differences between newborns, infants, older children and adolescents.- Explains relevant information about the maturation of the human body regarding absorption, distribution, metabolism and excretion of food and drugs, including key differences between newborns, infants, older children and adolescents- Discusses historical roots of separate drug approval in officially labeled "children" and conflicts of interest in performing and publishing "pediatric" research- Helps to decipher justifications for pediatric studies to help people navigate the relevance of the information
Frequently asked questions
- Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
- Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Information
Table of contents
- Cover image
- Title page
- Table of Contents
- Copyright
- Foreword by Jane M. Grant-Kels
- Foreword by David Neubauer
- Rumpelstiltskin and the miller’s daughter
- Conclusion and outlook
- Abbreviations and technical explanations
- Background
- Introduction
- Chapter 1. The process of modern drug development and the challenge of young patients
- Chapter 2. US and EU pediatric legislation
- Chapter 3. A paradigm shift
- Chapter 4. Introduction: specific disease areas
- Chapter 5. Neonatology
- Chapter 6. Challenges at the interface of science, drug development, and drug approval beyond specific disease areas
- Chapter 7. Juvenile animal studies
- Chapter 8. Child-friendly formulations: tablets, quick-dissolving formulations, liquids, and more
- Chapter 9. What do young patients really need?
- Index